immune system inflammation
Conditions
Interventions
None listed
Sponsors
Radboud Universitair Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Patient population 1. Have given written informed consent to participate 2. Be aged 40 years and over 3. Have symptomatic cerebral small vessel disease defined as: • Clinically symptomatic lacunar infarct in presence of white matter hyperintensities (Fazekas >=1) on MRI • and/or symptoms of cognitive impairment due to small vessel disease (Fazekas >= 1) with lacunar infarct on MRI • and/or gait apraxia/motor impairment presumed due to small vessel disease (Fazekas >= 1) with lacunar infarct on MRI If there is a recent history of stroke, baseline MRI will be scheduled at least 3 months after last stroke to exclude BBB changes secondary to acute infarction. Healthy control population 1. Have given written informed consent to participate 2. Be aged 40 years and over
Exclusion criteria
Exclusion criteria: Patient population - unable/unwilling to consent including lack of capacity to consent - vaccination or infection with fever in preceding month - any stroke cause other than SVD including: o Cardioembolic source o Carotid or vertebral stenosis >50% measured on NASCET criteria - Myocardial infarction in past year - Vasculitis - any chronic disease that could lead to brain lesions mimicking SVD (for example multiple sclerosis) - contraindications for 3 T MRI - auto-immune/auto-inflammatory disease - use of immunomodulating drugs - Estimated glomerular filtration rate (eGFR)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| White matter ultrastructure as assessed with MRI (being the most sensitive measure of cerebral small vessel disease) and relate this with markers of the immune and coagulation system. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Cognition and clinical (stroke, other cardiovascular disease) 2. BBB leakage on MRI 3. | — |
Countries
Netherlands
Outcome results
None listed